Ann: CLINUVEL Newsletter III - June 2024, page-22

I still find it interesting that more recent references I have seen (here and elsewhere) are. from mouse trials in the last two years. To be in a position to do a human trial (albeit n=6) at this point is reasonably good IMO. Those who followed UHO on google would have seen references to neurodegenerative trials in mice many years ago. Can't help thinking how many train wrecks there are looking for successful treatments or preventatives for stroke and these neurodegenerative diseases. I also noted some walking or gait difficulties with XP patients. A lot to work out but if CUV can reduce dopamine decline in PD and reduce damage in stroke that's pretty groundbreaking IMO. Of course that might not happen. I think Clinuvel know a lot more than most however on melanocortins and their effects in this area. GLTA